KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Share-based Compensation (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Share-based Compensation for 6 consecutive years, with $12.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 15.25% year-over-year to $12.9 million, compared with a TTM value of $55.8 million through Dec 2025, down 17.44%, and an annual FY2025 reading of $55.8 million, down 17.44% over the prior year.
  • Share-based Compensation was $12.9 million for Q4 2025 at AbCellera Biologics, down from $13.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $17.8 million in Q2 2024 and bottomed at $5.4 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $13.4 million, with a median of $14.1 million recorded in 2025.
  • The sharpest move saw Share-based Compensation skyrocketed 1298.18% in 2021, then decreased 20.1% in 2025.
  • Year by year, Share-based Compensation stood at $9.0 million in 2021, then surged by 47.41% to $13.3 million in 2022, then grew by 23.46% to $16.4 million in 2023, then dropped by 7.43% to $15.2 million in 2024, then decreased by 15.25% to $12.9 million in 2025.
  • Business Quant data shows Share-based Compensation for ABCL at $12.9 million in Q4 2025, $13.9 million in Q3 2025, and $14.2 million in Q2 2025.